Activity Date: 04/08/2019
Medication adherence is a recognized concern with most chronic health conditions in developed countries, with adherence rates estimated at 50%. The variables most significantly associated with non-adherence include patient’s attitude toward medication and therapeutic alliance. One avenue to tackle this obstacle is the utilization of technology, in the form of applications (apps), psychoeducation of the patient or family, electronic monitoring or telephone/texting interventions. A potential breakthrough area, medical condition management apps which includes medication-related apps, are now the fifth largest category of mobile health apps which have the potential to reach the more than 2 billion smartphone users. Medication reminder apps utilize a range of behavior change techniques to help promote adherence. Recent studies, however, reflect that most apps have not incorporated the advances in the field of health behavior change, nor have the apps been developed in collaboration with health care professionals. With over 400 apps available, the lack of strong evidence in specific patient populations, it is essential that pharmacists are educated about which apps are the most effective and have the potential to be incorporated into the regular care of patients living with mental illness instead of potentially using apps that lack beneficial features or are of poor quality.
In addition to encouraging the use of technology to enhance adherence, it is suggested that a strong therapeutic alliance may improve adherence including shared decision making (SDM). SDM is considered an ethical approach to educating and involving the patient and family in the treatment process. Ensuring adequate health care professional education and resource development, including decision-aids should be considered to ensure that SDM is used in an ethical format that truly incorporates patients and their families into the decision-making process instead of trying to convince them to make a preferred decision.
To receive ACPE credit for the live session at the Annual Meeting, you must:
This course will be provided at the CPNP 2019 Annual Meeting, April 7-10, 2019. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Michael O. Measom, MDView biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of knowledge-based continuing education credit from CPNP approved programming.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck